Physician profile
Daniel S Choi
NPI 1164413696
$34,507.32
in general payments reported to CMS, 2019-2025
31 companies · $5,551 in 2025
The $5,551 reported for 2025 was more than what 94% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,523 · 2020: $1,434 · 2021: $5,144 · 2022: $4,768 · 2023: $7,458 · 2024: $6,629 · 2025: $5,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $7,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,437.74 |
| Travel and Lodging | $7,199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $9,516.79 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $6,383.40 | 2019-2025 | General - Pain Management, General - Therapies, Wavewriter Alpha Prime 16 |
| Spinal Simplicity, LLC | $4,417.65 | 2022-2024 | Ha Minuteman G3-R |
| Relievant Medsystems, INC. | $4,014.51 | 2022-2023 | Intracept |
| Medtronic USA, INC. | $2,488.22 | 2019-2020 | |
| Si-Bone, INC. | $1,495.14 | 2019-2025 | |
| Abbott Laboratories | $1,025.04 | 2019-2024 | Proclaim |
| Abbvie INC. | $903.73 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Stryker Corporation | $764.04 | 2025 | Mild Device Kit |
| Aerie Pharmaceuticals, INC. | $616.07 | 2019 | |
| Electronic Waveform Lab, INC. | $473.74 | 2024-2025 | |
| Avanos Medical | $446.47 | 2020-2024 | Coolief* Cooled Radiofrequency, Generator |
| Biotronik Nro, INC. | $232.58 | 2023-2025 | Prospera, Biotronik |
| Vertex Pharmaceuticals Incorporated | $192.99 | 2025 | |
| Biotissue Holdings INC. | $192.29 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioness INC | $160.99 | 2019 | |
| Tersera Therapeutics LLC | $132.99 | 2019-2020 | |
| Vertiflex, INC. | $128.55 | 2019 | |
| Biogen, INC. | $125.16 | 2022-2025 | Spinraza, Qalsody |
| Dompe US, INC. | $125.00 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $116.25 | 2023 | Iovera |
| Radius Health, INC. | $102.16 | 2019-2021 | |
| Pfizer INC. | $89.98 | 2019-2021 | |
| Allergan, INC. | $84.02 | 2019-2021 | |
| Lundbeck LLC | $59.08 | 2023-2025 | Vyepti |
| Nevro Corp. | $59.01 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $57.78 | 2019-2020 | |
| Amgen INC. | $30.77 | 2019 | |
| Bioventus LLC | $30.47 | 2025 | Supartz Fx Sodium Hyaluronate |
| Daiichi Sankyo INC. | $23.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.01 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.